Whitehawk Therapeutics, Inc. (WHWK) Stock Price & Analysis
Whitehawk Therapeutics, Inc. (WHWK) closed at USD 3.04 on Thursday, October 15, 2026, up 2.36% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.97; the Oct 15, 2026 session ranged USD 2.98–3.08 on volume of 337,389 shares. Market capitalization is $173.31M, with a 52-week range of USD 1.97–5.5 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/WHWK.md
Key facts (WHWK)
- Analysts: Buy (mean 2.22 on a 1–5 scale) (9 analysts), mean target USD 7.71 (range 4–10).
- Total return with dividends: 1Y +16.5% vs S&P 500 +18.1%; 5Y -88.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.24, revenue estimate $0K.
Analysts (WHWK)
Consensus Buy (mean 2.22 on a 1–5 scale), 9 analysts; mean target USD 7.71 (low 4, high 10).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-01 | Stifel | Initiated | Buy | $9 |
| 2026-07-13 | Leerink Partners | Initiated | Outperform | $9 |
| 2026-06-25 | B. Riley Securities | Initiated | Buy | $10 |
Total return (dividends reinvested) (WHWK)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +16.5% | -88.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +16.5% | -35.4% |
| Volatility (annualized) | 74.0% | 68.4% |
| Max drawdown | -41.8% (May 2026→Oct 2026) | -95.2% (Nov 2021→Jul 2024) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 3.04 |
|---|---|
| Change | ▲ 2.36% (up) |
| Previous Close | USD 2.97 |
| Open | USD 2.98 |
| Day Range | USD 2.98 – 3.08 |
| 52-Week Range | USD 1.97 – 5.5 |
| Volume | 337,389 shares |
| Market Cap | $173.31M |
| Exchange | NCM |
Technical Analysis (WHWK)
Nexqual's technical model rates WHWK "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 21.03 (oversold) |
| vs SMA50 | Below (USD 4.19) |
| MACD | -0.29 (negative) |
Analyst Ratings (WHWK)
Wall Street analysts rate WHWK "Buy" based on 9 analysts, with a mean price target of USD 7.71 (range USD 4–10), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 7.71 |
| High Target | USD 10 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 6 / 3 / 0 |
Earnings (WHWK)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.24 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.2 vs est -0.26 ▲ beat |
| 2026-03-31 | USD -0.32 vs est -0.33 ▲ beat |
| 2025-12-31 | USD -0.34 vs est -0.27 ▼ miss |
| 2025-09-30 | USD -0.25 vs est -0.22 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (WHWK)
| Total Revenue | $0 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -44.98% |
| Current Ratio | 17.38 |
| Total Cash | $189.98M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (WHWK)
Nexqual rates Whitehawk Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Critical — Revenue -73% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $190M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$69M (TTM) |
| Efficiency | Critical — ROE -45%, ROA -28.7% |
Ownership (WHWK)
| Insider Ownership | +12.62% |
|---|---|
| Institutional Ownership | +81.10% |
| Shares Outstanding | 57.01M |
| Float | 28.74M |
| Short % of Float | +7.67% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (WHWK)
Whitehawk Therapeutics, Inc. is led by David J. Lennon (age 54), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| President, CEO & Director | David J. Lennon (age 54) |
|---|---|
| Founder & Director | Neil P. Desai (age 60) |
| CFO, Treasurer, Investor Relations & Corporate Communications | Scott M. Giacobello (age 55) |
| Chief Scientific Officer | David Dornan (age 47) |
Major Backers & Investors (WHWK)
Notable institutional backers of Whitehawk Therapeutics, Inc. include Yu Fan, Acuta Capital Partners LLC, QVT Financial LP, according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Yu Fan | 8.53% |
| Acuta Capital Partners LLC | 8.22% |
| QVT Financial LP | 8.1% |
| Montanova Capital LLC | 7.54% |
| Orbimed Advisors LLC. | 6.9% |
| Avoro Capital Advisors LLC | 5% |
| Siren, L.L.C. | 4.1% |
| Kvp Capital Advisors, LP | 3.8% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.37% |
| Vanguard Group | 4.83% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt